Genotoxicity of flubendazole and its metabolites in vitro and the impact of a new formulation on in vivo aneugenicity.

Journal Information

Full Title: Mutagenesis

Abbreviation: Mutagenesis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Environmental Health

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"The contribution of Covance Ltd staff in carrying out the cytogenetic studies reported in this article, is acknowledged, as is Accelera Pty Ltd for carrying out the Ames tests. Robert Don (DNDi) is thanked for his support of this work. We are grateful to Janssen Pharmaceutica N.V., Beerse, Belgium (a Johnson and Johnson Company) for supply of the flubendazole metabolites. The Drugs for Neglected Diseases initiative acknowledges financial support from the Bill & Melinda Gates Foundation (USA) for this work. The authors would like to acknowledge Dr John Wills (Health Canada post-doctoral fellow) who provided support in generating Figure 2."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025